
No added benefit can be derived from the indirect comparison presented in the drug manufacturer dossier, in particular because the studies on the appropriate comparator therapy were unsuitable, scientists say.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/yubAHlyloUs/141204103127.htm